RadioMedix Secures 5-Year Thorium-228 Supply Deal to Advance Targeted Alpha Therapy Pipeline
Key Insights
RadioMedix (search) has entered into a 5-year agreement with Van Overeem Nuclear B.V. (search) to secure thorium-228 (search) supply, expanding access to essential isotope resources for targeted alpha therapy development.
The partnership strengthens RadioMedix (search)'s lead-212 pipeline and RAHA-100 generator platform, positioning the company to meet future clinical and commercial demand for radiopharmaceuticals.
This supply agreement represents a significant step in building upstream infrastructure required to advance targeted alpha therapies as an emerging cancer (search) treatment modality.
RadioMedix (search), Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals for cancer (search) diagnosis and therapy, announced a 5-year frame agreement with Van Overeem Nuclear B.V. (search) for the supply of thorium-228 (search) (228Th). The partnership secures another critical upstream isotope source to support the company's development of lead-212 (212Pb) therapies and scale its generator platform for Targeted Alpha Therapy (TAT) radiopharmaceuticals.
Strategic Infrastructure Development
"Securing a reliable supply of 228Th is a fundamental step in building the long-term infrastructure required for 212Pb innovation," said Ebrahim S. Delpassand, M.D., Chief Executive Officer of RadioMedix (search). "As we advance our therapeutic pipeline and expand our RAHA-100 generator platform, establishing multiple upstream isotope sources ensures we can meet future clinical and commercial demand. This agreement strengthens a key part of that foundation and positions RadioMedix to help drive the next generation of targeted radiopharmaceutical therapies."
Under the agreement, Van Overeem Nuclear B.V. (search) will provide 228Th as the precursor for RadioMedix (search)'s production of 212Pb, supporting the company's advancing therapeutic pipeline and future manufacturing plans. The expanded supply of high-quality 228Th reinforces RadioMedix's capacity to increase access to clinical-grade 212Pb for TAT development through its proprietary bench top 212Pb RAHA-100 generator.
Advancing Cancer Treatment Modalities
Philippe van Overeem, Chief Executive Officer of Van Overeem Nuclear B.V. (search), emphasized the clinical significance of the partnership: "We are truly proud that our company is supplying RadioMedix (search) with this very important radionuclide. 212Pb will be a pivotal radionuclide in the treatment of different kinds of cancer (search). This agreement strengthens RadioMedix's supply chain and supports the continued advancement of TAT as an emerging modality with the potential to transform cancer treatment."
Supply Chain Expansion
This latest agreement broadens RadioMedix (search)'s global 228Th supplier network and represents a significant step in strengthening the upstream infrastructure required to advance TAT radiopharmaceuticals internally and for the broader field. The partnership expands RadioMedix's access to essential 228Th resources, strengthening the company's 212Pb pipeline and generator platform for its long-term Targeted Alpha Therapy strategy.
RadioMedix (search) operates The SPICA Center, a 27,000 square foot facility that leads the industry in radiopharmaceutical manufacturing and offers full-service support for academic and industry partners. Van Overeem Nuclear B.V. (search) is a Netherlands-based producer and supplier of medical radionuclides serving pharmaceutical, biotechnology, and research organizations worldwide, dedicated to delivering high-quality isotopes that support diagnostic and therapeutic advancements in nuclear medicine.